share_log

Janux Therapeutics Shares Are Trading Higher After the Company Announced Updated Interim Clinical Data for Its JANX007 Program in Prostate Cancer.

Janux Therapeutics Shares Are Trading Higher After the Company Announced Updated Interim Clinical Data for Its JANX007 Program in Prostate Cancer.

Janux Therapeutics的股票在公司公布了其JANX007前列腺癌项目的更新中期临床数据后上涨。
Benzinga ·  2024/12/03 20:24

Janux Therapeutics Shares Are Trading Higher After the Company Announced Updated Interim Clinical Data for Its JANX007 Program in Prostate Cancer.

Janux Therapeutics的股票在公司公布了其JANX007前列腺癌项目的更新中期临床数据后上涨。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发